tiprankstipranks
Abbott Laboratories (CH:ABT)
:ABT
Switzerland Market
ABT
Abbott Laboratories
RESEARCH TOOLSreports

Abbott Laboratories (ABT) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

ABT Analyst Ratings

Strong Buy
16Ratings
Strong Buy
14 Buy
2 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Abbott
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

CHF107.69
▲(30.53% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is CHF107.69 with a high forecast of CHF125.89 and a low forecast of CHF97.21. The average price target represents a 30.53% change from the last price of CHF82.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"81":"CHF81","126":"CHF126","92.25":"CHF92.3","103.5":"CHF103.5","114.75":"CHF114.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125.89290374,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF125.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107.6862401295,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF107.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.20844466,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF97.21</span>\n  </div></div>","useHTML":true}}],"tickPositions":[81,92.25,103.5,114.75,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.5,85.83791567230769,89.17583134461539,92.51374701692308,95.85166268923076,99.18957836153845,102.52749403384615,105.86540970615384,109.20332537846153,112.54124105076923,115.87915672307692,119.2170723953846,122.5549880676923,{"y":125.89290374,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.5,84.43740308688461,86.37480617376923,88.31220926065384,90.24961234753846,92.18701543442307,94.12441852130769,96.0618216081923,97.99922469507693,99.93662778196155,101.87403086884616,103.81143395573078,105.74883704261539,{"y":107.6862401295,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.5,83.63141882,84.76283764,85.89425646,87.02567528,88.1570941,89.28851292,90.41993174,91.55135056,92.68276938,93.8141882,94.94560702,96.07702584,{"y":97.20844466,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":91.756,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.508,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.508,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.508,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.014,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.014,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.014,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.488,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.498,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.498,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF125.89Average Price TargetCHF107.69Lowest Price TargetCHF97.21
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on CH:ABT
Vijay Kumar
Evercore ISI
Evercore ISI
CHF110.37→CHF107.17
Buy
29.91%
Upside
Assigned
04/06/26
Abbott price target lowered to $134 from $138 at Evercore ISIAbbott price target lowered to $134 from $138 at Evercore ISI
Wells Fargo Analyst forecast on CH:ABT
Larry Biegelsen
Wells Fargo
Wells Fargo
CHF97.58
Buy
18.28%
Upside
Reiterated
04/02/26
Analysts' Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT)
Erste Group Analyst forecast on CH:ABT
Unknown Analyst
Erste Group
Not Ranked
Erste Group
―
Hold
―
Reiterated
04/01/26
Erste Group Keeps Their Hold Rating on Abbott Laboratories (ABT)
BTIG Analyst forecast on CH:ABT
Marie Thibault
BTIG
BTIG
CHF111.97→CHF104.78
Buy
27.00%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Edwards Lifesciences (NYSE: EW) and Palisade Bio (NASDAQ: PALI)
Bank of America Securities Analyst forecast on CH:ABT
Travis Steed
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Abbott Laboratories (NYSE: ABT)
RBC Capital Analyst forecast on CH:ABT
Shagun Singh Chadha
RBC Capital
RBC Capital
CHF107.97
Buy
30.88%
Upside
Reiterated
03/25/26
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS), Merck & Company (NYSE: MRK) and Abbott Laboratories (NYSE: ABT)
UBS Analyst forecast on CH:ABT
Danielle Antalffy
UBS
UBS
CHF126.37
Buy
53.18%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Kura Oncology (NASDAQ: KURA)
Citi Analyst forecast on CH:ABT
Joanne Wuensch
Citi
Citi
CHF111.97→CHF108.77
Buy
31.85%
Upside
Assigned
03/12/26
Abbott price target lowered to $136 from $140 at CitiAbbott price target lowered to $136 from $140 at Citi
TD Cowen Analyst forecast on CH:ABT
Josh Jennings
TD Cowen
TD Cowen
CHF109.57
Buy
32.82%
Upside
Reiterated
02/13/26
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX) and Abbott Laboratories (NYSE: ABT)
Piper Sandler Analyst forecast on CH:ABT
Adam Maeder
Piper Sandler
Piper Sandler
CHF107.97
Buy
30.88%
Upside
Reiterated
02/06/26
Piper Sandler Sticks to Its Buy Rating for Abbott Laboratories (ABT)
Barclays Analyst forecast on CH:ABT
Matt Miksic
Barclays
Barclays
CHF113.57
Buy
37.66%
Upside
Reiterated
02/03/26
Analysts Are Bullish on These Healthcare Stocks: Qiagen (QGEN), Abbott Laboratories (ABT)
William Blair Analyst forecast on CH:ABT
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
02/03/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Maze Therapeutics, Inc. (NASDAQ: MAZE)
Oppenheimer Analyst forecast on CH:ABT
Suraj Kalia
Oppenheimer
Oppenheimer
CHF111.97→CHF105.57
Buy
27.97%
Upside
Reiterated
01/23/26
Abbott price target lowered to $132 from $140 at OppenheimerAbbott price target lowered to $132 from $140 at Oppenheimer
Jefferies Analyst forecast on CH:ABT
Matthew Taylor
Jefferies
Jefferies
CHF115.97
Buy
40.57%
Upside
Reiterated
01/23/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Maravai Lifesciences Holdings (NASDAQ: MRVI) and CVRx (NASDAQ: CVRX)
Mizuho Securities Analyst forecast on CH:ABT
Anthony Petrone
Mizuho Securities
Mizuho Securities
CHF111.97→CHF99.98
Hold
21.18%
Upside
Reiterated
01/23/26
Abbott price target lowered to $125 from $140 at MizuhoAbbott price target lowered to $125 from $140 at Mizuho
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on CH:ABT
Vijay Kumar
Evercore ISI
Evercore ISI
CHF110.37→CHF107.17
Buy
29.91%
Upside
Assigned
04/06/26
Abbott price target lowered to $134 from $138 at Evercore ISIAbbott price target lowered to $134 from $138 at Evercore ISI
Wells Fargo Analyst forecast on CH:ABT
Larry Biegelsen
Wells Fargo
Wells Fargo
CHF97.58
Buy
18.28%
Upside
Reiterated
04/02/26
Analysts' Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT)
Erste Group Analyst forecast on CH:ABT
Unknown Analyst
Erste Group
Not Ranked
Erste Group
―
Hold
―
Reiterated
04/01/26
Erste Group Keeps Their Hold Rating on Abbott Laboratories (ABT)
BTIG Analyst forecast on CH:ABT
Marie Thibault
BTIG
BTIG
CHF111.97→CHF104.78
Buy
27.00%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Edwards Lifesciences (NYSE: EW) and Palisade Bio (NASDAQ: PALI)
Bank of America Securities Analyst forecast on CH:ABT
Travis Steed
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Abbott Laboratories (NYSE: ABT)
RBC Capital Analyst forecast on CH:ABT
Shagun Singh Chadha
RBC Capital
RBC Capital
CHF107.97
Buy
30.88%
Upside
Reiterated
03/25/26
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS), Merck & Company (NYSE: MRK) and Abbott Laboratories (NYSE: ABT)
UBS Analyst forecast on CH:ABT
Danielle Antalffy
UBS
UBS
CHF126.37
Buy
53.18%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Kura Oncology (NASDAQ: KURA)
Citi Analyst forecast on CH:ABT
Joanne Wuensch
Citi
Citi
CHF111.97→CHF108.77
Buy
31.85%
Upside
Assigned
03/12/26
Abbott price target lowered to $136 from $140 at CitiAbbott price target lowered to $136 from $140 at Citi
TD Cowen Analyst forecast on CH:ABT
Josh Jennings
TD Cowen
TD Cowen
CHF109.57
Buy
32.82%
Upside
Reiterated
02/13/26
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX) and Abbott Laboratories (NYSE: ABT)
Piper Sandler Analyst forecast on CH:ABT
Adam Maeder
Piper Sandler
Piper Sandler
CHF107.97
Buy
30.88%
Upside
Reiterated
02/06/26
Piper Sandler Sticks to Its Buy Rating for Abbott Laboratories (ABT)
Barclays Analyst forecast on CH:ABT
Matt Miksic
Barclays
Barclays
CHF113.57
Buy
37.66%
Upside
Reiterated
02/03/26
Analysts Are Bullish on These Healthcare Stocks: Qiagen (QGEN), Abbott Laboratories (ABT)
William Blair Analyst forecast on CH:ABT
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
02/03/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Maze Therapeutics, Inc. (NASDAQ: MAZE)
Oppenheimer Analyst forecast on CH:ABT
Suraj Kalia
Oppenheimer
Oppenheimer
CHF111.97→CHF105.57
Buy
27.97%
Upside
Reiterated
01/23/26
Abbott price target lowered to $132 from $140 at OppenheimerAbbott price target lowered to $132 from $140 at Oppenheimer
Jefferies Analyst forecast on CH:ABT
Matthew Taylor
Jefferies
Jefferies
CHF115.97
Buy
40.57%
Upside
Reiterated
01/23/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Maravai Lifesciences Holdings (NASDAQ: MRVI) and CVRx (NASDAQ: CVRX)
Mizuho Securities Analyst forecast on CH:ABT
Anthony Petrone
Mizuho Securities
Mizuho Securities
CHF111.97→CHF99.98
Hold
21.18%
Upside
Reiterated
01/23/26
Abbott price target lowered to $125 from $140 at MizuhoAbbott price target lowered to $125 from $140 at Mizuho
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

3 Months
xxx
Success Rate
16/20 ratings generated profit
80%
Average Return
+4.05%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +4.05% per trade.
1 Year
Jayson BedfordRaymond James
Success Rate
36/45 ratings generated profit
80%
Average Return
+17.78%
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +17.78% per trade.
2 Years
xxx
Success Rate
15/20 ratings generated profit
75%
Average Return
+31.24%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +31.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
1
1
1
0
Buy
38
36
31
32
15
Hold
2
1
1
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
38
33
35
17
In the current month, ABT has received 15 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 107.69.
Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is CHF0.92 with a range of CHF0.90 to CHF0.95. The previous quarter’s EPS was CHF1.20. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.
Next quarter’s earnings estimate for ABT is CHF0.92 with a range of CHF0.90 to CHF0.95. The previous quarter’s EPS was CHF1.20. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is CHF8.80B with a range of CHF8.55B to CHF8.87B. The previous quarter’s sales results were CHF9.17B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.
Next quarter’s sales forecast for ABT is CHF8.80B with a range of CHF8.55B to CHF8.87B. The previous quarter’s sales results were CHF9.17B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Stock Forecast FAQ

What is CH:ABT’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 107.69.
    What is CH:ABT’s upside potential, based on the analysts’ average price target?
    Abbott Laboratories has 30.53% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbott Laboratories a Buy, Sell or Hold?
          Abbott Laboratories has a consensus rating of Strong Buy, which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Abbott Laboratories’s share price target?
            The average share price target for Abbott Laboratories is 107.69. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF125.89 ,and the lowest forecast is CHF97.21. The average share price target represents 30.53% Increase from the current price of CHF82.5.
              What do analysts say about Abbott Laboratories?
              Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of Abbott Laboratories?
                To buy shares of CH:ABT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.